- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Omar Nadeem, MD | Authors
Selection and Duration of Therapy in Transplant-Ineligible NDMM
June 29, 2022
Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.
Patient Profile 2: A 72-Year-Old With Transplant-Ineligible NDMM
June 29, 2022
The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.
Duration of Therapy in NDMM
June 22, 2022
Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.
Selecting Appropriate Therapy for Transplant-Eligible NDMM
June 22, 2022
Panelists briefly review factors they use to select induction therapy for patients with transplant-eligible, newly diagnosed multiple myeloma.
Quadruplet Vs Triplet Induction Regimens for Transplant-Eligible NDMM
June 15, 2022
Shared insight on approved quadruplet vs triplet induction regimens for patients with transplant-eligible, newly diagnosed multiple myeloma, evaluated in the GRIFFIN, MASTER and GMMG-HD7 trials.
Patient Profile 1: A 62-Year-Old With Transplant-Eligible NDMM
June 15, 2022
Experts discuss a patient with transplant-eligible, newly diagnosed multiple myeloma managed with induction daratumumab-RVd and maintenance therapy.